ClinicalTrials.gg
Not yet recruitingNCT07200622Updated Oct 1, 2025

Oral Semaglutide in Patients With Alzheimer's Disease

A Phase 2 interventional study of Semaglutide (Rybelsus®) and Placebo in Alzheimer Disease, sponsored by Imperial College London. Not yet recruiting. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2025-10-01.

Sponsored by Imperial College London · Phase 2, Interventional, and Treatment

How we know · 4 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Alzheimer Disease by Imperial College London — 6 open to participants now, 7 under way, 1 of them phase 3. Alzheimer Disease · Imperial College London.

Started
2025
with 3 others
Phase 2
4 of 11
3 open now
Registered
10th of 11
by date

Among the 11 studies in Alzheimer Disease by Imperial College London, this one is one of 4 that started in 2025, is one of 4 in phase 2, and was the 10th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

6 of the 11 studies in Alzheimer Disease by Imperial College London are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Alzheimer Disease by Imperial College London, or all of them as a file.
02

Study summary

Alzheimer's disease (AD) is a progressive neurodegenerative disease and a major global healthcare burden. Currently, the disease is only treated symptomatically and an effective disease-modifying therapy (DMT) that may slow the disease progression, and prevent cognitive and functional deterioration, is yet to emerge. Glucagon-like peptide-1 (GLP-1) analogues are being studied to treat neurodegenerative diseases, due to evidence of their neuroprotective effects in mouse models of AD. This study investigates Semaglutide, a modified human GLP-1RA in Alzheimer's disease to understand the mechanism of the disease. The primary objective of this study is to evaluate the safety and tolerability of oral semaglutide in individuals with mild AD. Moreover, the secondary objective of the study is to evaluate the change in synaptic density using PET before and after treatment with semaglutide.

03

Conditions studied

  • Alzheimer Disease

Browse trials for

Keywords

  • GLP-1 Analogues
  • Semaglutide
  • Alzheimers
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Capable of giving and capacity to give .
  2. An individual who can act as a reliable study partner with regular contact
  3. Diagnosis of Alzheimer's disease according to the revised NIA-AA criteria
  4. Age from 50 years
  5. (MMSE) score of ≥18; likely complete all the assessments
  6. Rosen Modified Hachinski Ischemic score ≤4
  7. On stable medication for 2 months before the screening visit; on or off cholinesterase inhibitors
  8. Fluency in English and evidence of adequate premorbid intellectual functioning
  9. Likely to be able to participate in all scheduled evaluations and complete all required tests

Exclusion criteria

Exclusion Criteria:

  1. Any to the use of oral semaglutide
  2. Significant neurological disease other than AD that may affect cognition
  3. MRI/CT showing unambiguous aetiological evidence of cerebrovascular disease with regard to their dementia or vascular dementia fulfilling NINCDSAIREN criteria
  4. Current presence of a major psychiatric disorder
  5. Current clinically significant systemic illness that is likely to result in deterioration of the subject's condition or affect the subject's safety during the study
  6. Myocardial infarction within the last 1 year
  7. Other clinically significant abnormality on physical, neurological or laboratory examination that could compromise the study or be detrimental to the subject
  8. History of alcohol or drug dependence within the last 2 years
  9. Current use of narcotic medications which could affect cognition. Subjects on anticoagulants will be allowed, but will not have an arterial line inserted
  10. Women of . Women who could become pregnant will be required to use adequate throughout the trial. Please see appendix A for more information. All women of childbearing potential will take a pregnancy test before the PET scan.
  11. Any contraindications to MRI scanning
  12. Any historical evidence of pancreatitis or gallstones as proven by ultrasound or medical admission.
  13. History of medullary thyroid cancer
  14. Patients diagnosed with T2DM who are unwilling to change their treatment to semaglutide.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Semaglutide (Rybelsus)

    Drug: Semaglutide (Rybelsus®)

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugSemaglutideStudies of SemaglutideSemaglutide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    All subjects will receive oral semaglutide once daily (4-weekly dose escalation from 3 mg to 7 mg and finally 14 mg). This dose escalation schedule is specified in the IMP (Rybelsus) SmPC.

  • DrugPlacebo

    Matched oral Placebo to be taken once daily.

06

What researchers measure

Primary outcomes

  1. To evaluate the safety and tolerability of oral semaglutide in an AD population.

    To assess the safety and tolerability of (1-year) Semaglutide treatment in patients with AD using composite outcome measure of the adverse events evaluated from the safety assessments. This will be assessed by the number of participants using a composite measure generated from abnormal vital signs, abnormal 12-lead ECG readings, abnormal laboratory (blood) tests, abnormalities found in MRI scans, abnormal physical exam findings, and abnormal neurological/psychiatric evaluation.

    Time frame: Adverse events monitoring: Baseline; Weeks 4, 8, 26, 39, 52

Secondary outcomes

  1. To evaluate the change in synaptic density using [18F] SynVesT-1 before and after treatment.

    Synaptic density will be assessed, using \[18F\] SynVesT-1, at baseline and after 1-year of treatment with Semaglutide.

    Time frame: [18F] SynVesT-1 PET will be conducted at baseline and Week 52 (end of treatment).

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2025; primary completion for Dec 2027, 27 months later.

Of 128 non-industry phase 2 interventional studies under Alzheimer Disease, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 69. This study's planned 27 months is below that.

Counting every sponsor, half of 259 studies reached it within 37 months; a quarter within 21 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2025
First posted
Oct 1, 2025
StartEst.
Sep 25, 2025
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2028
Last update
Oct 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07200622
Responsible party
Sponsor
First posted
Oct 1, 2025
Start date
Sep 25, 2025 (estimated)
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Oct 1, 2025

Study contacts

Paul Edison, MD, PhD, FRCP, FRCPI
Contact
paul.edison@imperial.ac.uk
+44 2075941083

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Semaglutide

Start the discussion